跳至主要内容
临床试验/2024-520127-89-00
2024-520127-89-00招募中4 期

GASPS Study: General Anaesthesia vs Spinal anaesthesia: Patient outcomes and Success in Outpatient primary total knee and hip Arthroplasty

Region Oerebro Laen2 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2026年4月1日最近更新:
干预措施

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
600
试验地点
2
主要终点
Successful same-day discharge, defined as: • The patient is discharged from the hospital on the same day as the surgery and, • the patient is not readmitted within 48 hours of discharge.

研究概览

简要总结

To determine whether the use of General anaesthesia (GA) compared to Spinal anaesthesia (SA) is associated with a higher frequency of successful same-day discharge in patients undergoing outpatient TKA and THA Successful same-day discharge is defined as: • Discharge on the day of surgery, and • No readmission within 48 hours of discharge.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • The participant has given their written consent to participate in the trial.
  • Planned for primary TKA or THA.
  • Adults aged 18 to 80 years at time of written consent.
  • ASA (American Society of Anesthesiologists) classification 1 or 2, or 3 without significant functional impairment.
  • Scheduled start of surgery before 13:
  • Ability to communicate in Swedish, ensuring understanding of informed consent and follow-up procedures.

排除标准

  • Indication for surgery other than degenerative or inflammatory joint diseases (e.g. fracture).
  • Women of childbearing potential (i.e., those who are fertile, following menarche and until becoming post-menopausal, unless permanently sterile) a. Who are not willing to use a highly effective method of contraception judged by the investigator, from the time of signing the informed consent, OR b. Who has a positive pregnancy test at enrolment
  • Individual unwilling or unable to receive either spinal or general anaesthesia
  • Participation or recent participation in a clinical trial with an investigational medicinal product within 30 days.
  • Previous participation in this trial.
  • Body mass index (BMI) > 35 kg/m.
  • Preoperative opioid use exceeding 20 mg oral morphine equivalents daily.
  • Haemoglobin <120 g/L (sample no older than 3 months).
  • Known bleeding disorders, including coagulopathies.
  • Known allergies to investigational anaesthetic drugs (e.g., bupivacaine, remifentanil, or propofol).
  • Neurological conditions with persistent motor or sensory deficits.
  • Localised infections at the spinal injection site.
  • Determined by the surgical or anaesthesia team to be unsuitable for trial participation and/or outpatient surgery.

研究组 & 干预措施

REMIFENTANIL , PROPOFOL

Test

干预措施: REMIFENTANIL (Drug)

REMIFENTANIL , PROPOFOL

Test

干预措施: PROPOFOL (Drug)

BUPIVACAINE, SUFENTANIL , FENTANYL

Comparator

干预措施: BUPIVACAINE (Drug)

BUPIVACAINE, SUFENTANIL , FENTANYL

Comparator

干预措施: SUFENTANIL (Drug)

BUPIVACAINE, SUFENTANIL , FENTANYL

Comparator

干预措施: FENTANYL (Drug)

结局指标

主要结局

Successful same-day discharge, defined as: • The patient is discharged from the hospital on the same day as the surgery and, • the patient is not readmitted within 48 hours of discharge.

Successful same-day discharge, defined as: • The patient is discharged from the hospital on the same day as the surgery and, • the patient is not readmitted within 48 hours of discharge.

次要结局

  • Time from start of anaesthesia to start of surgery (Phase II).
  • Time from start of surgery to discharge from the postoperative recovery unit (Phase II).
  • Time from start of surgery to fulfilment of indicators for end phase III (intermediate recovery) as outlined in the protocol (table 4).
  • Time from start of surgery to discharge from hospital (Phase III).
  • Time from start of surgery to first successful mobilisation, assessed by the ability to walk with tolerable pain and ascend/descend stairs if applicable.
  • Use of analgesics (opioids converted to Oral morphine equivalents (OME)).
  • Patient-reported quality of recovery using the Swedish Version of Quality of Recovery - 15 (QoR-15) from postoperative day (POD) 1 to POD 35.
  • Pain levels measured using the Numeric Rating Scale (NRS) during the recovery period (postoperative until discharge to ward)
  • Knee injury and Osteoarthritis Outcome Score (KOOS) at baseline, 4 weeks, 6 months 12 months.
  • Hip disability and Osteoarthritis Outcome Score (HOOS), at baseline, 4 weeks, 6 months 12 months.
  • Use of analgesics (opioids converted to Oral morphine equivalents (OME)). Daily postoperative day 1-14, weekly day 15-35
  • Incidence, severity and frequency of adverse events (AEs) and serious adverse events (SAEs), until postoperative day 3.
  • Incidence and frequency of predefined adverse outcomes. (Table 1), until postoperative day 3.
  • Units of blood transfusion, until discharge from hospital
  • Key themes from patient-reported experiences of anaesthesia and postoperative care, gathered through semi-structured interviews conducted 14–60 days post-surgery.
  • Incremental cost-effectiveness ratios (ICERs) comparing costs and quality-adjusted life years (QALYs) gained between GA and SA.

研究者

发起方
Region Oerebro Laen
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Kristofer Nilsson

Scientific

Region Oerebro Laen

研究点 (2)

Loading locations...

相似试验